FI952260A0 - Propiofenonijohdos ja menetelmä sen valmistamiseksi - Google Patents

Propiofenonijohdos ja menetelmä sen valmistamiseksi

Info

Publication number
FI952260A0
FI952260A0 FI952260A FI952260A FI952260A0 FI 952260 A0 FI952260 A0 FI 952260A0 FI 952260 A FI952260 A FI 952260A FI 952260 A FI952260 A FI 952260A FI 952260 A0 FI952260 A0 FI 952260A0
Authority
FI
Finland
Prior art keywords
glucopyranosyl
preparation
beta
propiophenone derivative
groups
Prior art date
Application number
FI952260A
Other languages
English (en)
Swedish (sv)
Other versions
FI952260A (fi
FI116975B (fi
Inventor
Kenji Tsujihara
Mitsuya Hongu
Nobuyuki Funami
Masanori Inmasu
Kenji Arakawa
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of FI952260A0 publication Critical patent/FI952260A0/fi
Publication of FI952260A publication Critical patent/FI952260A/fi
Application granted granted Critical
Publication of FI116975B publication Critical patent/FI116975B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
FI952260A 1994-05-11 1995-05-10 Propiofenonijohdannainen ja menetelmä sen valmistamiseksi FI116975B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP9680594 1994-05-11
JP9680594 1994-05-11
JP28234494 1994-11-17
JP28234494 1994-11-17

Publications (3)

Publication Number Publication Date
FI952260A0 true FI952260A0 (fi) 1995-05-10
FI952260A FI952260A (fi) 1995-11-12
FI116975B FI116975B (fi) 2006-04-28

Family

ID=26437976

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952260A FI116975B (fi) 1994-05-11 1995-05-10 Propiofenonijohdannainen ja menetelmä sen valmistamiseksi

Country Status (15)

Country Link
US (1) US5830873A (fi)
EP (1) EP0684254B1 (fi)
KR (1) KR100318793B1 (fi)
CN (1) CN1042637C (fi)
AT (1) ATE178069T1 (fi)
AU (1) AU680118B2 (fi)
BR (1) BR9502016A (fi)
CA (1) CA2149160C (fi)
DE (1) DE69508463T2 (fi)
DK (1) DK0684254T3 (fi)
ES (1) ES2133614T3 (fi)
FI (1) FI116975B (fi)
GR (1) GR3029795T3 (fi)
IL (1) IL113581A (fi)
MY (1) MY119134A (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
JP3059088B2 (ja) * 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
ATE216704T1 (de) * 1996-12-26 2002-05-15 Tanabe Seiyaku Co Propiophenonderivate und verfahren zu ihrer herstellung
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6838442B2 (en) * 2001-04-04 2005-01-04 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators
JP4590159B2 (ja) * 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
AU2004261663A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
EP1680414A4 (en) * 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED INDAZOLE-O-GLUCOSIDE
EP1679965A4 (en) * 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES
WO2005012243A2 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
CN103819465A (zh) * 2003-08-01 2014-05-28 田边三菱制药株式会社 新颖化合物
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
TWI365186B (en) * 2005-01-31 2012-06-01 Mitsubishi Tanabe Pharma Corp Indole derivatives
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
ES2397664T3 (es) * 2006-12-04 2013-03-08 Janssen Pharmaceutica, N.V. Derivados de glucopiranósilo que contienen tienilo como antidiabéticos
PT2200606T (pt) 2007-09-10 2017-12-13 Janssen Pharmaceutica Nv Processo para a preparação de compostos úteis como inibidores de sglt
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CA2725047A1 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
WO2011003976A1 (en) 2009-07-10 2011-01-13 Janssen Pharmaceutica Nv CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL] BENZENE
CA2777528C (en) * 2009-10-14 2018-09-18 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
WO2011143296A1 (en) 2010-05-11 2011-11-17 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
PL2697218T3 (pl) 2011-04-13 2016-11-30 Sposób wytwarzania związków użytecznych, jako inhibitory SGLT2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
EP3823631A1 (en) 2018-07-19 2021-05-26 Astrazeneca AB Methods of treating hfpef employing dapagliflozin and compositions comprising the same
WO2022022865A1 (en) 2020-07-27 2022-02-03 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
EP4315350A1 (en) 2021-04-01 2024-02-07 AstraZeneca UK Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984394A (en) * 1971-05-14 1976-10-05 Nutrilite Products, Inc. Salts of dihydrochalcone derivatives and their use as sweeteners
US4031260A (en) * 1971-05-14 1977-06-21 Nutrilite Products, Inc. Salts of dihydrochalcone derivatives and their use as sweeteners
US4049715A (en) * 1973-10-01 1977-09-20 Sterling Drug Inc. 3-[2-(4-Anisidino)phenyl]-1-phenyl-1-propiophenones and propanols
US4684627A (en) * 1981-09-08 1987-08-04 Leveen Harry H Treatment of cancer with phlorizin and its derivatives
US5110801A (en) * 1984-08-13 1992-05-05 Leveen Harry H Treatment of acne
CA1289077C (en) * 1984-08-13 1991-09-17 Harry H. Leveen Treatment of cancer with phlorizin and its derivatives
US4760135A (en) * 1984-09-06 1988-07-26 University Of Kentucky Research Foundation Phloretin and phlorizin derivative containing compounds
US4665058A (en) * 1985-03-16 1987-05-12 The University Of Kentucky Research Foundation Compositions and method of treatment for sickle cell anemia
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent

Also Published As

Publication number Publication date
MY119134A (en) 2005-04-30
DE69508463D1 (de) 1999-04-29
CA2149160A1 (en) 1995-11-12
EP0684254B1 (en) 1999-03-24
EP0684254A1 (en) 1995-11-29
CA2149160C (en) 2002-01-29
GR3029795T3 (en) 1999-06-30
CN1042637C (zh) 1999-03-24
FI952260A (fi) 1995-11-12
DK0684254T3 (da) 1999-10-11
US5830873A (en) 1998-11-03
AU680118B2 (en) 1997-07-17
KR100318793B1 (ko) 2002-07-04
ATE178069T1 (de) 1999-04-15
BR9502016A (pt) 1995-12-12
KR950032262A (ko) 1995-12-20
ES2133614T3 (es) 1999-09-16
AU1779095A (en) 1995-11-16
IL113581A (en) 1999-07-14
FI116975B (fi) 2006-04-28
CN1121925A (zh) 1996-05-08
DE69508463T2 (de) 1999-08-19
IL113581A0 (en) 1995-08-31

Similar Documents

Publication Publication Date Title
FI952260A0 (fi) Propiofenonijohdos ja menetelmä sen valmistamiseksi
AU696851B2 (en) Method of treating hyperproliferative vascular disease
HU9600834D0 (en) Quinazoline derivatives
IL113894A0 (en) Oxalylamino-benzofuran- and benzothienyl-derivatives process for their preparation pharmaceutical compositions containing them and their use
AP2001002291A0 (en) Novel method of treatment.
PT876388E (pt) Derivados de eritromicina triciclica
NO20001169L (no) 6,9-bro erythromycinderivater
CA2307788A1 (en) 2-halo-6-o-substituted ketolide derivatives
NO20001439L (no) 3'-N-modifiserte 6-O-substituerte erytromycin ketolid- derivater med antibakteriell aktivitet
CA2202032A1 (en) Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof
AU5754294A (en) Use of a pregnane derivative
IL125951A (en) A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
AU2012195A (en) Glucopyranoside benzothiophenes
HUT52478A (en) Process for producing glycerin derivatives and pharmaceutical compositions comprising same
DE69627519D1 (de) Sesquiterpen-derivate mit antiviraler aktivität
IL130052A0 (en) Method of treating glaucoma and ischemic retinopathy
BR9508521A (pt) Inibição da biossintese de leucotrienos com derivados de uréia
FI941850A (fi) Uusi yhdiste, joka on leustroduksiini H, sen valmistus ja terapeuttinen käyttö
BG103985A (en) Multicyclic derivatives of erythromycin
GB9323403D0 (en) Pharmaceuticals

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 116975

Country of ref document: FI

MA Patent expired